324 related articles for article (PubMed ID: 7482438)
1. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
2. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
3. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
6. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
[TBL] [Abstract][Full Text] [Related]
8. Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor 1 complexes in Hep G2 cells.
Underhill DM; Owensby DA; Morton PA; Schwartz AL
Blood; 1992 Dec; 80(11):2746-54. PubMed ID: 1333299
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
10. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Bu G; Maksymovitch EA; Schwartz AL
J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff hepatoma cells.
Nguyen G; Self SJ; Camani C; Kruithof EK
J Biol Chem; 1992 Mar; 267(9):6249-56. PubMed ID: 1313432
[TBL] [Abstract][Full Text] [Related]
12. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
14. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
[TBL] [Abstract][Full Text] [Related]
15. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Bu G; Morton PA; Schwartz AL
J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
[TBL] [Abstract][Full Text] [Related]
16. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
17. The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes.
Wing LR; Bennett B; Booth NA
FEBS Lett; 1991 Jan; 278(1):95-7. PubMed ID: 1847116
[TBL] [Abstract][Full Text] [Related]
18. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
Lee JA; Croucher DR; Ranson M
Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
